BR0214023A - Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina - Google Patents

Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina

Info

Publication number
BR0214023A
BR0214023A BR0214023-3A BR0214023A BR0214023A BR 0214023 A BR0214023 A BR 0214023A BR 0214023 A BR0214023 A BR 0214023A BR 0214023 A BR0214023 A BR 0214023A
Authority
BR
Brazil
Prior art keywords
melanocortin receptor
receptor modulators
thiadiazole derivatives
derivatives
useful
Prior art date
Application number
BR0214023-3A
Other languages
English (en)
Inventor
Magdalena Eisinger
Louis J Fitzpatrick
Daniel H Lee
Kevin Pan
Carlos Plata-Salaman
Allen B Reitz
Virginia L Smith-Swintosky
Boyu Zhao
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of BR0214023A publication Critical patent/BR0214023A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018—Esters of cycloaliphatic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

"DERIVADOS DE 1,2,4-TIADIAZóLIO COMO MODULADORES DE RECEPTOR DE MELANOCORTINA". A presente invenção refere-se a derivados de 1,2,4-tiadiazol-2-io da fórmula (1): onde R^ 1^, R^ 2^ e R^ 4^ são radicais contendo anel, e R^ 3^ é H, alquila, alquenila ou alquinila, úteis como agonistas ou antagonistas do receptor de melanocortina. Mais particularmente, os compostos da presente invenção são úteis para o tratamento de distúrbios metabólicos, do SNC e dermatológicos.
BR0214023-3A 2001-11-08 2002-11-05 Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina BR0214023A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33776201P 2001-11-08 2001-11-08
PCT/US2002/035365 WO2003040118A1 (en) 2001-11-08 2002-11-05 Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators

Publications (1)

Publication Number Publication Date
BR0214023A true BR0214023A (pt) 2004-11-23

Family

ID=23321888

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214023-3A BR0214023A (pt) 2001-11-08 2002-11-05 Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina

Country Status (25)

Country Link
US (4) US7319107B2 (pt)
EP (1) EP1444215B1 (pt)
JP (1) JP4491235B2 (pt)
CN (1) CN100422164C (pt)
AR (1) AR037284A1 (pt)
AT (1) ATE333449T1 (pt)
AU (1) AU2002340372B2 (pt)
BR (1) BR0214023A (pt)
CA (1) CA2466145A1 (pt)
CY (1) CY1105233T1 (pt)
DE (1) DE60213276T2 (pt)
DK (1) DK1444215T3 (pt)
ES (1) ES2268108T3 (pt)
IL (2) IL161830A0 (pt)
MX (1) MXPA04004457A (pt)
MY (1) MY134994A (pt)
NO (1) NO328194B1 (pt)
NZ (1) NZ532884A (pt)
PT (1) PT1444215E (pt)
RS (1) RS51199B (pt)
RU (1) RU2323932C2 (pt)
SI (1) SI1444215T1 (pt)
TW (1) TWI317358B (pt)
WO (1) WO2003040118A1 (pt)
ZA (1) ZA200404487B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7319107B2 (en) * 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
PT1446394E (pt) * 2001-11-08 2007-01-31 Ortho Mcneil Pharm Inc Novos derivados de 1,2,4-tiadiazole como moduladores do receptor da melanocortina
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US8460243B2 (en) * 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) * 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
JP2007523197A (ja) * 2004-02-23 2007-08-16 プロレキシーズ ファーマシューティカルズ インコーポレイテッド ｐＨＳＰ２０様活性を有する非ペプチジル剤、およびその使用
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2858901C (en) 2004-06-04 2024-01-16 Carolyn Anderson Diabetes care host-client architecture and data management system
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
US20070016256A1 (en) 2005-07-18 2007-01-18 Korb Donald R Method and apparatus for treating gland dysfunction
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20070060988A1 (en) * 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US7981145B2 (en) * 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981146B2 (en) * 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) * 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8527313B2 (en) * 2006-05-15 2013-09-03 Sap Ag Document instantiation triggering a business action
US8007524B2 (en) * 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US7976573B2 (en) * 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7981147B2 (en) * 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008027069A1 (en) * 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
USD613408S1 (en) 2008-02-06 2010-04-06 Tearscience, Inc. Eye treatment head gear
USD617443S1 (en) 2008-02-06 2010-06-08 Tearscience, Inc. Eye treatment goggles
ES2453640T3 (es) 2008-02-21 2014-04-08 Janssen Pharmaceutica N.V. Métodos para el tratamiento de desordenes dermatológicos
US8377925B2 (en) 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
CA2743489A1 (en) 2008-11-17 2010-05-20 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
CA2995880C (en) 2009-01-16 2021-01-05 Exelixis, Inc. Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
BRPI1013853A2 (pt) * 2009-04-24 2019-09-24 Janssen Pharmaceuticals Inc composições tópicas estáveis de derivados de 1,2,4-tiadiazol
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011508A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
ES2360783B1 (es) * 2009-10-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
USD638128S1 (en) 2009-10-06 2011-05-17 Tearscience, Inc. Ocular device design
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011156246A1 (en) 2010-06-11 2011-12-15 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2628734A4 (en) * 2010-10-15 2014-04-23 Federalnoe G Bydzhetnoe Uchrezhdenie Nauki Inst Fiziol Aktivnikh Veschestv Rossiiskoi Akademii Nauk DERIVATIVES OF 5-AMINO - [1,2,4] THIADIAZOLE
US9018395B2 (en) 2011-01-27 2015-04-28 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
EP2683376B1 (en) * 2011-03-07 2018-11-28 Celgene Corporation Methods for treating diseases using isoindoline compounds
PL3539551T3 (pl) 2011-12-29 2022-02-21 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych z receptorem melanokortyny 4 u heterozygotycznych nosicieli
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
ES2942724T3 (es) 2013-04-30 2023-06-06 Alcon Inc Sistemas para el tratamiento de enfermedades del ojo
JP6714589B2 (ja) 2014-10-31 2020-06-24 リポテック， エセ．ア． Ｐｓｅｕｄｏａｌｔｅｒｏｍｏｎａｓ ａｎｔａｒｃｔｉｃａ由来の細菌性細胞外生成物を含有する化粧品組成物および／または医薬組成物ならびにその使用
CA3000670A1 (en) 2015-09-30 2017-04-06 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
WO2019195756A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
CN115381955B (zh) * 2021-05-24 2024-05-17 中国科学技术大学 黑皮质素受体mc5r的用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE131373C (pt)
DD131373A1 (de) 1977-06-17 1978-06-21 Juergen Liebscher Verfahren zur herstellung von 2,3-disubstituierten 5-dialkylamino-1,2,4-thiadiazoliumsalzen
JPS6011481A (ja) 1983-06-30 1985-01-21 Nippon Soda Co Ltd １，２，４−チアジアゾ−ル系誘導体及び農園芸用殺菌剤
JPH02173165A (ja) 1988-12-27 1990-07-04 Nippon Soda Co Ltd 防汚剤
DE69708198T2 (de) * 1996-04-30 2002-03-28 Pfizer Inc., New York Muscarinische Rezeptor-Agonisten
US20020103194A1 (en) * 1997-04-30 2002-08-01 Anabella Villalobos Novel muscarinic receptor agonists
EP1076649A4 (en) 1998-04-28 2010-06-02 Trega Biosciences Inc ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE
DE59913665D1 (de) * 1998-04-29 2006-08-24 Merck Patent Gmbh Verfahren zur katalytischen herstellung von substituierten bipyridylderivaten
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU1324300A (en) 1998-10-26 2000-05-15 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
AU2001228681A1 (en) 2000-01-28 2001-08-07 Melacure Therapeutics Ab Novel aromatic amines and amides acting on the melanocortin receptors
JP2003527444A (ja) * 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
US6728804B1 (en) 2000-10-27 2004-04-27 Emware, Inc. Remotely reprogrammable communications adapter for providing access to an electronic device
US7319107B2 (en) * 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
PT1446394E (pt) 2001-11-08 2007-01-31 Ortho Mcneil Pharm Inc Novos derivados de 1,2,4-tiadiazole como moduladores do receptor da melanocortina
US7435429B2 (en) * 2002-02-07 2008-10-14 Trustees Of Columbia University In The City Of New York Zinc salt compositions for the prevention of dermal and mucosal irritation
ES2453640T3 (es) * 2008-02-21 2014-04-08 Janssen Pharmaceutica N.V. Métodos para el tratamiento de desordenes dermatológicos
BRPI1013853A2 (pt) * 2009-04-24 2019-09-24 Janssen Pharmaceuticals Inc composições tópicas estáveis de derivados de 1,2,4-tiadiazol

Also Published As

Publication number Publication date
CN1612869A (zh) 2005-05-04
JP2005511606A (ja) 2005-04-28
US7786311B2 (en) 2010-08-31
NO20042373L (no) 2004-06-07
DE60213276T2 (de) 2007-07-19
EP1444215B1 (en) 2006-07-19
TW200303310A (en) 2003-09-01
RS39604A (en) 2006-10-27
CY1105233T1 (el) 2010-03-03
IL161830A0 (en) 2005-11-20
RU2004114208A (ru) 2005-09-10
DE60213276D1 (de) 2006-08-31
RU2323932C2 (ru) 2008-05-10
US8501791B2 (en) 2013-08-06
MY134994A (en) 2008-01-31
PT1444215E (pt) 2006-10-31
AU2002340372B2 (en) 2008-12-11
SI1444215T1 (sl) 2006-12-31
DK1444215T3 (da) 2006-11-06
CA2466145A1 (en) 2003-05-15
US20030162819A1 (en) 2003-08-28
US20090203751A1 (en) 2009-08-13
ES2268108T3 (es) 2007-03-16
EP1444215A1 (en) 2004-08-11
MXPA04004457A (es) 2005-06-08
NZ532884A (en) 2006-06-30
US7319107B2 (en) 2008-01-15
ZA200404487B (en) 2006-08-30
CN100422164C (zh) 2008-10-01
AR037284A1 (es) 2004-11-03
US20100280079A1 (en) 2010-11-04
RS51199B (sr) 2010-12-31
NO328194B1 (no) 2010-01-04
ATE333449T1 (de) 2006-08-15
TWI317358B (en) 2009-11-21
JP4491235B2 (ja) 2010-06-30
US20060030604A1 (en) 2006-02-09
WO2003040118A1 (en) 2003-05-15
IL161830A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
BR0214023A (pt) Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina
BR0214024A (pt) Derivados de 1,2,4-tiadiazol como moduladores de receptor de melanocortina
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
BR0312575A (pt) Moduladores do receptor de glicocorticóides
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BR0012697A (pt) Inibidores da diferenciação de th2
BR0014761A (pt) Derivados de benzodiazepina
BR0311494A (pt) Novos indóis substituìdos
BR9915420A (pt) Composto, composição farmacêutica, métodos de tratar um distúrbio mediado por tnf e por p38 cinase, inflamação e artrite e processo de preparar pirazóis
UY26130A1 (es) Compuestos para tratar la obesidad
BR0312729A (pt) Novos derivados de indol-3-enxofre
NO20032208D0 (no) Benzodiazepinderivater som GABA A reseptormodulatorer
BR9910029A (pt) Hidróxi indóis, sua aplicação como inibidores da fosfodiesterase 4 e processo para sua preparação
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
TNSN02012A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
BR0308787A (pt) Inibidores de metaloproteinase de n-substituìdos-heteroarilóxi-aril-espiro-pirimidina- 2,4,6-triona
BR0311541A (pt) indol, azaindol e 4-aquenil piperidina amidas heterocìclicas relacionadas
BR0206943A (pt) Inibidores de fosfodiesterase 4
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
BR0206738A (pt) Derivados tricìclicos de lactama e de sultama e uso dos mesmos como inibidores de histona desacetilase
BR9808366A (pt) Derivados de ácido hidroxâmico substituìdo com aril ou heteroaril sulfonamidas; processo para sua preparação e seu uso como produtos farmacêuticos
BR0112093A (pt) Derivados de sulfonil-pirrolidina úteis no tratamento de distúrbios neurológicos
BR0213094A (pt) Derivados de cromano como ligandos de 5-hidroxi-triptamina-6
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DK0982992T3 (da) Anvendelse af thienopyrimidiner som fungicider

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: ORTHO-MC NEIL PHARMACEUTICAL, INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]